Loading...

Marc Shuman, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address600 16th Street
San Francisco CA 94158
Phone415-476-2125
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    UCSF PROSTATE CANCER SPORE
    NIH/NCI P50CA089520Sep 25, 2000 - Jun 30, 2010
    Role: Co-Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - May 31, 2018
    Role: Co-Investigator
    Proteases in Cancer Biology and Drug Development
    NIH/NCI P01CA072006Jun 10, 1997 - Jun 30, 2010
    Role: Co-Principal Investigator
    TRANSFUSION BIOLOGY AND MEDICINE
    NIH/NHLBI P50HL054476Feb 1, 1996 - Dec 31, 2006
    Role: Co-Principal Investigator
    UROKINASE RECEPTOR IN PROSTATE DEVELOPMENT AND CANCER
    NIH/NCI R01CA059545Aug 15, 1993 - Jul 31, 1997
    Role: Principal Investigator
    SPORE in Breast Cancer
    NIH/NCI P50CA058207Sep 30, 1992 - Nov 30, 2013
    Role: Co-Investigator
    BIOSYNTHESIS AND GENETICS OF GLYCOPROTEINS IIB AND IIIA
    NIH/NHLBI R01HL033277Dec 1, 1984 - Nov 30, 1993
    Role: Principal Investigator
    Basic Research in Hematology and Oncology
    NIH/NIDDK T32DK007636May 1, 1984 - Mar 31, 2014
    Role: Principal Investigator
    PROTEINASE-INHIBITOR REACTIONS IN CORNEAL ENDOTHELIUM
    NIH/NEI R01EY004882Jul 1, 1983 - Sep 29, 1989
    Role: Principal Investigator
    CELLULAR REGULATION OF BLOOD CLOTTING
    NIH/NHLBI R01HL021403Dec 1, 1981 - Nov 30, 1992
    Role: Principal Investigator
    MECHANISM OF ACTIVATION OF COAGULATION AND PLATELETS
    NIH/NHLBI K04HL000802Dec 1, 1980 - Nov 30, 1985
    Role: Principal Investigator
    BLOOD BANKING SCIENCES AND RELATED PROGRAMS
    NIH/NHLBI T32HL007100Jul 1, 1975 - Jun 30, 1996
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman M, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 Dec 01; 126(12):4640-4653. PMID: 27841764.
      View in: PubMed
    2. Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, Yang H, Wang TA, Stehbens SJ, Younger S, Barshow S, Zhu S, Cooper MK, Peacock J, Ramaswamy V, Garzia L, Wu X, Remke M, Forester CM, Kim CC, Weiss WA, James CD, Shuman M, Bader GD, Mueller S, Taylor MD, Jan YN, Jan LY. EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci. 2015 Sep; 18(9):1236-46. PMID: 26258683; PMCID: PMC4639927.
    3. Ge F, Wang DD, Li L, Lin PP, Shuman M. WITHDRAWN: Enhanced Detection and Phenotypic and Karyotypic in Situ Characterization of Circulating Tumor Cells. Am J Pathol. 2014 Oct 17. PMID: 25451150.
      View in: PubMed
    4. Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman M, Rubenstein JL. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41. PMID: 24190981; PMCID: PMC3944388.
    5. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman M, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51. PMID: 23197589; PMCID: PMC3563362.
    6. Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Wang J, Chiang C, Cooper MK, Northcott PA, Taylor MD, Barnes MJ, Tihan T, Chen J, Hackett CS, Weiss WA, James CD, Rowitch DH, Shuman M, Jan YN, Jan LY. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev. 2012 Aug 15; 26(16):1780-96. PMID: 22855790; PMCID: PMC3426758.
    7. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman M, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15; 18(4):1146-55. PMID: 22228634; PMCID: PMC3288204.
    8. Huang V, Place RF, Portnoy V, Wang J, Qi Z, Jia Z, Yu A, Shuman M, Yu J, Li LC. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 2012 Feb; 40(4):1695-707. PMID: 22053081; PMCID: PMC3287204.
    9. Sun C, Su KH, Valentine J, Rosa-Bauza YT, Ellman JA, Elboudwarej O, Mukherjee B, Craik CS, Shuman M, Chen FF, Zhang X. Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors. ACS Nano. 2010 Feb 23; 4(2):978-84. PMID: 20121209; PMCID: PMC2884196.
    10. So AY, de la Fuente E, Walter P, Shuman M, Bernales S. The unfolded protein response during prostate cancer development. Cancer Metastasis Rev. 2009 Jun; 28(1-2):219-23. PMID: 19172382.
      View in: PubMed
    11. Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman M, Lowell CA, Treseler PA, James CD, Rubenstein JL. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009 Mar 15; 15(6):1989-97. PMID: 19276270; PMCID: PMC4372389.
    12. Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman M. Differential gene expression in central nervous system lymphoma. Blood. 2009 Jan 01; 113(1):266-7; author reply 267-8. PMID: 19122120; PMCID: PMC2614638.
    13. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman M, Jones T, Becker CH, Schulman H, Rubenstein JL. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008 Jan 01; 26(1):96-105. PMID: 18056677; PMCID: PMC4134101.
    14. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007 Apr 10; 25(11):1350-6. PMID: 17312328.
      View in: PubMed
    15. Chan JM, Feraco A, Shuman M, Hernández-Díaz S. The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am. 2006 Aug; 20(4):797-809. PMID: 16861115.
      View in: PubMed
    16. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006 May 01; 107(9):3716-23. PMID: 16418334; PMCID: PMC1895776.
    17. Reddy JC, Shuman M, Aster RH. Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med. 2004 Jan 26; 164(2):218-20. PMID: 14744847.
      View in: PubMed
    18. Bhatt AS, Takeuchi T, Ylstra B, Ginzinger D, Albertson D, Shuman M, Craik CS. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem. 2003 Feb; 384(2):257-66. PMID: 12675519.
      View in: PubMed
    19. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman M. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003 Jan 15; 101(2):466-8. PMID: 12393404.
      View in: PubMed
    20. Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M. Hemorrhage and VEGF expression in a case of primary CNS lymphoma. J Neurooncol. 2002 May; 58(1):53-6. PMID: 12160141.
      View in: PubMed